IMMUNOLOGICAL MECHANISMS OF RESISTANCE TO CDK4/CDK6 INHIBITORS IN BREAST CANCER

被引：1
|
作者：
Petroni, Giulia [1 ]
Gouin, Kenneth [2 ]
Martinez, Aitziber Buque [1 ]
Knott, Simon [2 ]
Formenti, Silvia [1 ]
Galluzzi, Lorenzo [1 ,3 ]
机构：
[1] Weill Cornell Med Coll, Brooklyn, NY USA
[2] Cedars Sinai, Los Angeles, CA USA
[3] Weill Cornell Med, New York, NY USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2021年 / 9卷
关键词：
D O I：
10.1136/jitc-2021-SITC2021.733
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
733
引用
收藏
页码：A763 / A763
页数：1
相关论文
共 50 条
  • [21] The Role of CDK4/6 Inhibitors in Breast Cancer
    Murphy, Conleth G.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2019, 20 (06)
  • [22] The Role of CDK4/6 Inhibitors in Breast Cancer
    Conleth G. Murphy
    Current Treatment Options in Oncology, 2019, 20
  • [23] CDK4/6 inhibitors in luminal breast cancer
    Gnant, Michael
    Steger, Guenther G.
    Bartsch, Rupert
    LANCET ONCOLOGY, 2015, 16 (01): : 2 - 3
  • [24] Targeting prostate cancer with the CDK4 and CDK6 inhibitor abemaciclib
    Torres-Guzman, Raquel
    Baquero, Carmen
    Patricia Ganado, Maria
    Marugan, Carlos
    Bian, Huimin
    Zeng, Yi
    Rama, Ramon
    Du, Jian
    Jose Lallena, Maria
    CANCER RESEARCH, 2020, 80 (16)
  • [25] Discovery of mechanisms that modulate the hippo pathway and CDK6 expression in CDK4/6 inhibitor resistant breast cancer cells
    Yu, Chung-Jen
    Zhuang, Yong-Ji
    Lin, Ting-Yi
    Chao, Ta-Chung
    Liu, Chun-Yu
    Tseng, Ling-Ming
    Lai, Jiun-I
    CANCER RESEARCH, 2023, 83 (07)
  • [26] Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft
    Raub, Thomas J.
    Wishart, Graham N.
    Kulanthaivel, Palaniappan
    Staton, Brian A.
    Ajamie, Rose T.
    Sawada, Geri A.
    Gelbert, Lawrence M.
    Shannon, Harlan E.
    Sanchez-Martinez, Concepcion
    De Dios, Alfonso
    DRUG METABOLISM AND DISPOSITION, 2015, 43 (09) : 1360 - 1371
  • [27] Nafamostat mesylate overcomes endocrine resistance of breast cancer through epigenetic regulation of CDK4 and CDK6 expression
    Lin, Yueh-Te
    Lin, Joseph
    Liu, Yi-En
    Hsu, Kai-Wen
    Hsieh, Chang-Chi
    Chen, Dar-Ren
    Wu, Han-Tsang
    TRANSLATIONAL ONCOLOGY, 2022, 15 (01):
  • [28] Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
    Abeer J. Al-Qasem
    Carla L. Alves
    Sidse Ehmsen
    Martina Tuttolomondo
    Mikkel G. Terp
    Lene E. Johansen
    Henriette Vever
    Luna V. A. Hoeg
    Daniel Elias
    Martin Bak
    Henrik J. Ditzel
    npj Precision Oncology, 6
  • [29] Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
    Al-Qasem, Abeer J.
    Alves, Carla L.
    Ehmsen, Sidse
    Tuttolomondo, Martina
    Terp, Mikkel G.
    Johansen, Lene E.
    Vever, Henriette
    Hoeg, Luna V. A.
    Elias, Daniel
    Bak, Martin
    Ditzel, Henrik J.
    NPJ PRECISION ONCOLOGY, 2022, 6 (01)
  • [30] The Evolving Pathways of the Efficacy of and Resistance to CDK4/6 Inhibitors in Breast Cancer
    Gomes, Ines
    Abreu, Catarina
    Costa, Luis
    Casimiro, Sandra
    CANCERS, 2023, 15 (19)
12345